NCT06656091View on ClinicalTrials.gov

A Study of Simmitinib Versus Chemotherapy for Participants With Advanced Oesophageal Squamous Cell Carcinoma

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

450

Participants

Timeline

Start Date

October 31, 2024

Primary Completion Date

January 30, 2027

Study Completion Date

January 30, 2027

Conditions

Advanced Oesophageal Squamous Cell Carcinoma

Interventions

DRUG

simmitinib

simmitinib 6mg,QD ,3 weeks on 1 week off

DRUG

investigator's choice of chemotherapy,include docetaxel or irinotecan.

docetaxel injection 75mg/m\^2,d1,every 3 weeks or ilinotecan injection 180mg/m\^2,d1,every 2 weeks

All Listed Sponsors

lead

Shanghai Runshi Pharmaceutical Technology Co., Ltd

INDUSTRY

NCT06656091 - A Study of Simmitinib Versus Chemotherapy for Participants With Advanced Oesophageal Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter